Pediatric Transplantation · 2015 · 23 citations · 30 references
MedicinePediatricsSurgeryPediatric EndocrinologyTransplant ImmunologyTransplant SurgeryLiver Transplant ImmunosuppressionLiver TransplantationPediatric Liver DiseasePediatric Transplant SurgeryPediatric TransplantationTransplant RejectionCardiometabolic DiseaseHypertension After TransplantationLong-term Cardiometabolic RiskMedian AgeMedical IndicationMetabolic Complications After TransplantationMultivisceral TransplantationPediatric Biliary Atresia Transplantation
UNLABELLED: PTMS describes the presence of ≥3 cardiometabolic risk factors that include obesity, hypertension, dyslipidemia, and IR. The prevalence of the clustering of ≥3 cardiometabolic risk factors or central obesity has not been studied in pediatric LT recipients. Single-center, cross-sectional study. INCLUSION CRITERIA: LT recipients 2-18 yr-old, at least one yr post-LT. EXCLUSION CRITERIA: recipients of liver retransplants or multivisceral transplants. Eighty-seven patients were identified. Median age was 9.8 yr (range 2-18), median time since LT was 6.9 yr (range 1-17). The most common indication for LT was biliary atresia (56%), and the most frequently used immunosuppressant was tacrolimus (80%). The prevalence of overweight and obesity was 21% and 5%, respectively. Central obesity affected 14%, hypertension 44%, IR 27%, low HDL 20%, and hypertriglyceridemia 39% of patients. The prevalence of ≥3 cardiometabolic risk factors was 19%. Fifty percent of the overweight/obese patients had ≥3 risk factors. Time since transplant, immunosuppression and renal function were not different between those with <3 or ≥3 risk factors. Clustering of cardiometabolic risk factors is prevalent in pediatric LT recipients, suggesting an increased risk of future CV events.
30
Prevalence of the Metabolic Syndrome Among US Adults
Earl S. Ford, Wayne H. Giles, William H. Dietz · JAMA · 2002 · 6.7K citations